Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma (I-MAT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04291885 |
Recruitment Status :
Recruiting
First Posted : March 2, 2020
Last Update Posted : April 15, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Merkel Cell Carcinoma Merkel Cell Carcinoma, Stage I Merkel Cell Carcinoma, Stage II Merkel Cell Carcinoma, Stage III Neuroendocrine Tumors Carcinoma Neuroendocrine Skin | Drug: Avelumab Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 132 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | Double-blind |
Primary Purpose: | Treatment |
Official Title: | A Randomised, Placebo-controlled, Phase II Trial of Adjuvant Avelumab in Patients With Stage I-III Merkel Cell Carcinoma |
Actual Study Start Date : | October 26, 2020 |
Estimated Primary Completion Date : | April 1, 2027 |
Estimated Study Completion Date : | April 1, 2028 |
Arm | Intervention/treatment |
---|---|
Experimental: Avelumab
6 months of Avelumab at a dose of 800mg as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)
|
Drug: Avelumab
Avelumab IV infusion
Other Names:
|
Placebo Comparator: Placebo
6 months of Placebo as a 60-minute intravenous (IV) infusion once every 2 weeks (13 doses)
|
Drug: Placebo
Placebo IV infusion |
- Recurrence-free survival (RFS) [ Time Frame: 24 Months ]Recurrence-free survival (RFS) as the primary endpoint, is anticipated to be analysed over an average planned follow-up of 3.5 years. An analysis of RFS at the 24 month time point of follow-up will also be conducted as it is anticipated that the minimum follow-up for participants will be 24 months and the sample size rationale utilises RFS rates at 24 months in historical controls. RFS is defined as the time from treatment initiation until the first date of any signs or symptoms of recurrence of tumour.
- Overall survival (OS) [ Time Frame: 24 Months ]Overall survival rates at 12 and 24 months. Overall survival is defined as the time from treatment initiation to the date of death due to any cause.
- Disease-specific survival (DSS) [ Time Frame: 24 Months ]Disease-specific survival at 24 months from treatment initiation. Disease-specific survival is the percentage of participants who have not died from Merkel Cell Carcinoma
- Rate of loco-regional failure free survival (LRFFS) [ Time Frame: 24 Months ]Rate of loco-regional failure free survival (LRFFS) is defined as the time from treatment initiation to the first recurrence of the loco-regional tumour.
- Distant metastasis-free survival (DMFS) [ Time Frame: 24 Months ]DMFS is defined as the time from treatment initiation to the first evidence of distant metastatic disease.
- Treatment toxicity and tolerability as assessed by NCI CTCAE v5.0 [ Time Frame: 24 Months ]Rate of treatment-related adverse events (AEs). Safety will be measured by serious adverse events (SAEs) and AEs assessed as per NCI CTCAE v5.0, including immune-related adverse events.
- Patient-reported quality of life (QoL) as assessed by FACT-M questionnaire [ Time Frame: 24 Months ]FACT-M form (version 4) will be utilised. This will include patient-reported questions relating to physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing and additional patient concerns which are measured from 0-4 (Not at all - Very Much).
- Rate of Merkel cell polyomavirus positivity in stage I-III Merkel cell carcinoma [ Time Frame: 24 Months ]To identify Merkel cell polyomavirus MCPyV virus status. To correlate viral aetiology-rate of Merkel cell polyomavirus (MCPyV) positivity in pathology specimens in stage I-III Merkel cell carcinoma with outcome from adjuvant treatment.
- Correlating whole exome sequencing (WES) and ribonucleic acid (RNA) expression with immunotherapy response and outcomes in early stage MCC [ Time Frame: 24 Months ]To evaluate the relationship between somatic mutations in cancer genes or the total mutation burden of the cancer with immunotherapy response and outcome following adjuvant therapy.
- Correlating immune infiltrates by multiplex immunohistochemistry (IHC) with survival endpoints [ Time Frame: 24 Months ]To address whether immune infiltrates and PD-L1 expression are associated with survival.
- Utility of circulating biomarkers in predicting recurrence in early stage MCC [ Time Frame: 24 Months ]To identify predictive biomarkers for response and resistance to immunotherapy in patients with stage I-III MCC using archival tissue and peripheral blood.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Histologically confirmed Merkel cell carcinoma (MCC) which is either:
- clinical stage I;
- pathological stage I with positive LVSI only;
- clinical or pathological stage II (including IIA and IIB);
- clinical or pathological stage III (including IIIA and IIIB).
- Absence of distant metastatic disease on baseline 18-Fludeoxyglucose (18FDG) - Positron Emission Tomography (PET) / Computed Tomography (CT) scan.
- 18 years of age or older.
- Eastern Cooperative Oncology Group (ECOG) of 0 - 2.
- Willing and able to provide written informed consent and comply with all study requirements.
- Adequate haematological, liver and renal function as determined by the screening laboratory values outlined in the protocol obtained within 14 days prior to randomisation.
- Agreeable to collection of archival tumour material. Where possible, the most recently acquired tumour specimen should be provided.
- Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy test within 72 hours prior to the start of treatment.
Exclusion Criteria:
- Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest significant risk for immune-related adverse events.
- Prior treatment with an agent that blocks the PD-1/PD-L1 pathway.
- Previous cancer immunotherapy, specifically interferon, anti-CD137, or anti-CTLA-4 antibody or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways are not permitted.
- Prior treatment with other immune-modulating agents that was within fewer than 28 days prior to the first dose of Avelumab.
- Active infection requiring antibiotics within 7 days of study entry.
- Active tuberculosis.
- Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- Uncontrolled infection with hepatitis B or hepatitis C virus (HBV or HCV) infection; Patients with previously successfully treated HCV, with positive anti-HCV antibody but undetectable (HCV) ribonucleic acid (RNA) levels are allowed on trial.
- Current use of immunosuppressive medication, except for the following: a. intranasal, inhaled, topical steroids, or local steroid injection ; b. systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. steroids as premedication for hypersensitivity reactions
- Any systemic anti-cancer treatment (chemotherapy, targeted systemic therapy) investigational or standard of care, within 28 days of the first dose of Avelumab or planned to occur during the study period. Patients receiving bisphosphonates or denosumab will not be excluded.
- Pregnant or breastfeeding.
- History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organising pneumonia (i.e., bronchiolitis obliterans, cryptogenic organising pneumonia), or evidence of active pneumonitis on screening chest CT scan).
- Uncontrolled cardiac disease including not limited to symptomatic congestive heart failure, unstable angina pectoris, life-threatening cardiac arrhythmia
- Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v5 Grade 3).
- Use of live attenuated vaccines within 28 days of first dose of Avelumab.
- Any acute or chronic psychiatric problems that, in the opinion of the Investigator, make the patient ineligible for participation due to compliance concerns.
- Patients with prior allogeneic stem cell or solid organ transplantation.
- Patients who are involuntarily incarcerated.
- No evidence of other malignancy in the past 3 years, with exception of tumours with negligible risk of metastasis or death.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04291885
Contact: Melanoma and Skin Cancer Trials Ltd Project officer | +61 3 9903 9022 | imat@masc.org.au |
Study Chair: | Wen Xu, MBBS, FRACP | Princess Alexandra Hospital |
Responsible Party: | Melanoma and Skin Cancer Trials Limited |
ClinicalTrials.gov Identifier: | NCT04291885 |
Other Study ID Numbers: |
03.18 |
First Posted: | March 2, 2020 Key Record Dates |
Last Update Posted: | April 15, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Carcinoma, Merkel Cell Carcinoma Neuroendocrine Tumors Carcinoma, Neuroendocrine Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue |
Polyomavirus Infections DNA Virus Infections Virus Diseases Infections Tumor Virus Infections Adenocarcinoma Avelumab Antineoplastic Agents, Immunological Antineoplastic Agents |